243 related articles for article (PubMed ID: 37885090)
21. A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.
Zhu Z; Zhao Q; Song W; Weng J; Li S; Guo T; Zhu C; Xu Y
Front Immunol; 2022; 13():940774. PubMed ID: 36248908
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
23. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
24. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
[TBL] [Abstract][Full Text] [Related]
25. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
26. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
[TBL] [Abstract][Full Text] [Related]
28. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
[TBL] [Abstract][Full Text] [Related]
29. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z
Front Immunol; 2022; 13():925618. PubMed ID: 35898502
[TBL] [Abstract][Full Text] [Related]
30. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
32. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
33. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
34. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.
Ding L; Li W; Tu J; Cao Z; Li J; Cao H; Liang J; Liang Y; Yu Q; Li G
Front Immunol; 2022; 13():989156. PubMed ID: 36177029
[TBL] [Abstract][Full Text] [Related]
35. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
Li W; Zhang X; Chen Y; Pang D
Front Oncol; 2022; 12():966511. PubMed ID: 36212436
[TBL] [Abstract][Full Text] [Related]
36. Copper metabolism-related risk score identifies hepatocellular carcinoma subtypes and SLC27A5 as a potential regulator of cuproptosis.
Li X; Wang J; Guo Z; Ma Y; Xu D; Fan D; Dai P; Chen Y; Liu Q; Jiao J; Fan J; Wu N; Li X; Li G
Aging (Albany NY); 2023 Dec; 15(24):15084-15113. PubMed ID: 38157255
[TBL] [Abstract][Full Text] [Related]
37. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
[TBL] [Abstract][Full Text] [Related]
38. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
[TBL] [Abstract][Full Text] [Related]
39. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
40. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]